STOCK TITAN

Savara (SVRA) Stock News, Dec 2024-Mar 2025

SVRA NASDAQ

Savara Inc. develops therapies for rare respiratory diseases, with a lead program in molgramostim inhalation solution, conditionally named MOLBREEVI, for autoimmune pulmonary alveolar proteinosis. Molgramostim is a recombinant human GM-CSF delivered through an investigational eFlow Nebulizer System developed for inhalation of the large-molecule therapy.

Recurring company developments include clinical data from the IMPALA-2 program, regulatory submissions and agency-review updates in the U.S., Europe and the U.K., financial results, financing arrangements, equity inducement grants and investor conference participation. Savara's updates also note that MOLBREEVI is not approved in any indication.

Rhea-AI Summary

Savara Inc. (SVRA) has completed the submission of its Biologics License Application (BLA) to the FDA for MOLBREEVI, a potential first-ever treatment for autoimmune Pulmonary Alveolar Proteinosis (aPAP). The company has requested Priority Review, which could reduce FDA review time from ten to six months.

The IMPALA-2 trial demonstrated statistically significant improvements in lung function, meeting its primary endpoint of improved pulmonary gas exchange (DLCO) at Week 24, with sustained benefits through Week 48. The treatment showed clinical benefits in respiratory quality (SGRQ scores) and exercise capacity (METs), with a strong safety profile as 97% of patients completed the trial.

MOLBREEVI has received multiple regulatory designations, including Fast Track, Breakthrough Therapy, and Orphan Drug status. Savara plans to submit a Marketing Authorization Application in Europe by end-2025, with a potential U.S. commercial launch in early 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
-
Rhea-AI Summary

Savara Inc. (SVRA) announced the acceptance of two posters for presentation at the American Thoracic Society (ATS) International Conference in May 2025. The presentations will showcase new data from the Phase 3 IMPALA-2 trial of Molgramostim inhalation solution for treating autoimmune Pulmonary Alveolar Proteinosis (aPAP).

The first poster will present results showing how Molgramostim reduces surfactant burden and whole lung lavage procedures in aPAP patients. The second poster will discuss the treatment's effects on respiratory health-related quality of life and patient-reported outcomes. Both abstracts will be published in the American Journal of Respiratory and Critical Care Medicine.

Additionally, Savara will host an Industry Theater session titled 'Advances in Autoimmune Pulmonary Alveolar Proteinosis' featuring experts Dr. Bruce Trapnell and Dr. Cormac McCarthy, who will discuss aPAP's pathophysiology, symptoms, diagnosis, and management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.66%
Tags
conferences clinical trial
-
Rhea-AI Summary

Savara Inc. (SVRA) has launched the aPAP ClearPath™ Dried Blood Spot (DBS) Test in the U.S., advancing their diagnostic capabilities for autoimmune pulmonary alveolar proteinosis (aPAP). This new test requires only a finger-prick blood sample and has demonstrated 100% analytical sensitivity and specificity in detecting GM-CSF autoantibodies.

Developed in partnership with TrilliumBiO's CLIA-certified lab, the test is offered at no cost and provides a convenient alternative to traditional venous blood draws. The company is currently finalizing its rolling BLA submission for MOLBREEVI™, their potential first-ever FDA-approved aPAP treatment, targeted for completion by the end of Q1 2025.

aPAP is a rare lung disease where antibodies neutralize GM-CSF, preventing proper surfactant clearance in the lungs, leading to breathing difficulties and potential serious complications including lung fibrosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its upcoming participation in the Leerink Global Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, March 11th at 10:40am ET/7:40am PT.

The event will be accessible through a live webcast and will remain available for replay on Savara's corporate website under the 'Events & Presentations' section for 90 days following the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
none
-
Rhea-AI Summary

Savara Inc. (SVRA) has granted inducement awards to five new employees, as announced by the company's Compensation Committee on February 12, 2025. The awards include:

- Stock options to purchase 97,500 shares with an exercise price of $2.75 per share, vesting quarterly over four years (1/16th per quarter)
- Restricted stock units (RSUs) covering 82,500 shares, vesting fully after two years

These equity awards were granted under Savara's 2021 Inducement Equity Incentive Plan, complying with NASDAQ Listing Rule 5635(c)(4). The stock options have a 10-year term, and both options and RSUs are subject to continued employment through their respective vesting dates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
Rhea-AI Summary

Savara Inc. (SVRA) announced the publication of a manuscript in ERJ Open Research detailing long-term outcomes of molgramostim inhalation solution in treating autoimmune pulmonary alveolar proteinosis (aPAP). The retrospective study evaluated five aPAP patients who received molgramostim through European single-patient access over a mean duration of 4.2 years.

The study demonstrated significant improvements including enhanced lung function, decreased disease burden, and reduced clinical symptoms. Key findings showed improvements in pulmonary gas transfer and activities of daily living. Notably, while four patients required whole lung lavage (WLL) before treatment, none needed it after one year of molgramostim use. The treatment was well-tolerated with no serious adverse events reported.

Savara plans to complete its rolling Biologics License Application (BLA) submission in the U.S. by the end of Q1 2025 and submit a Marketing Authorization Application (MAA) in Europe by the end of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
none
Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in two major healthcare investor conferences in February 2025.

The company's management team will participate in fireside chats at both events:

  • The Guggenheim SMID Cap Biotech Conference (February 5-6, 2025), with a fireside chat scheduled for February 5th at 10:00am ET/7:00am PT
  • The Oppenheimer 35th Annual Healthcare Life Sciences Conference (February 11-12, 2025), with a fireside chat scheduled for February 11th at 8:00am ET/5:00am PT

Live webcasts and replays will be accessible through Savara's corporate website in the 'Events & Presentations' section, remaining available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
conferences
-
Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA) has granted inducement awards to five new employees as announced by the Compensation Committee of its Board of Directors on December 20, 2024. The awards include options to purchase 100,000 shares of common stock at $3.23 per share and restricted stock units (RSUs) covering 100,000 shares.

The equity awards were granted under Savara's 2021 Inducement Equity Incentive Plan per NASDAQ Rule 5635(c)(4). The options have a 10-year term with quarterly vesting of 1/16th of shares, while RSUs fully vest after two years, both subject to continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
-
Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA) has initiated a rolling submission of a Biologics License Application (BLA) to the FDA for MOLBREEVI, targeting the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease. The company expects to complete the BLA submission by the end of Q1 2025 and will request priority review.

MOLBREEVI has received multiple regulatory designations including Fast Track, Breakthrough Therapy, and Orphan Drug Designation from both FDA and EMA. The drug demonstrated positive results in the Phase 3 IMPALA-2 trial, showing a favorable benefit-risk profile. If approved, MOLBREEVI would be the first approved treatment for aPAP in the U.S. and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.95%
Tags
Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's Chair and CEO, Matt Pauls, will present on January 15 at 5:15pm PT/8:15pm ET at the Westin St. Francis in San Francisco. The presentation will be available via live webcast and will remain accessible for 30 days on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.21%
Tags
none

FAQ

What is the current stock price of Savara (SVRA)?

Savara (SVRA) last closed at $4.64.

What is the market cap of Savara (SVRA)?

The market cap of Savara (SVRA) is approximately $1.0B.